Renal transplant recipients have elevated frequencies of circulating myeloid-derived suppressor cells

Nephrology Dialysis Transplantation

Volumn 27, Issue 1, 2012, Pages 402-410

  Hock, Barry D ^a   MacKenzie, Katarzyna A ^a,b   Cross, Nicholas B ^a   Taylor, Karen G ^a   Currie, Margaret J ^b   Robinson, Bridget A ^a,b   Simcock, Jeremy W ^a   McKenzie, Judith L ^a  

^a CHRISTCHURCH HOSPITAL   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

carcinoma; cell; dendritic cell; myeloid derived suppressor cells; renal; squamous; transplant

Indexed keywords

CD14 ANTIGEN; FORMYLMETHIONYLLEUCYLPHENYLALANINE; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 10;

ADULT; AGED; ARTICLE; CANCER RISK; CELL COUNT; CELL POPULATION; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG USE; EXTRACELLULAR SPACE; FEMALE; FLOW CYTOMETRY; GRAFT RECIPIENT; HUMAN; KIDNEY TRANSPLANTATION; LYMPHOCYTE PROLIFERATION; MALE; MITOSIS INHIBITION; MYELOID DENDRITIC CELL; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; SUPPRESSOR CELL; T LYMPHOCYTE ACTIVATION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CROSS-SECTIONAL STUDIES; DENDRITIC CELLS; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; IMMUNOCOMPETENCE; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYELOID CELLS; PROGNOSIS; SKIN NEOPLASMS; TUMOR ESCAPE;

EID: 84856668746     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr264     Document Type: Article

References (43)

1. Ulrich C, Kanitakis J, Stockfleth E et al. Skin cancer in organ transplant recipients-where do we stand today? Am J Transplant 2008; 8: 2192-2198
2. Grulich AE, van Leeuwen MT, Falster MO et al. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007; 370: 59-67 (Pubitemid 47017468)
3. Stewart TJ, Abrams SI. How tumours escape mass destruction. Oncogene 2008; 27: 5894-5903
4. Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 2009; 182: 4499-4506
5. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9: 162-174
6. Ko JS, Zea AH, Rini BI et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 2009; 15: 2148-2157
7. Hoechst B, Ormandy LA, Ballmaier M et al. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(1)CD25(1)Foxp3(1) T cells. Gastroenterology 2008; 135: 234-243 (Pubitemid 351899008)
8. Filipazzi P, Valenti R, Huber V et al. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol 2007; 25: 2546-2553 (Pubitemid 47041228)
9. Haile LA, von Wasielewski R, Gamrekelashvili J et al. Myeloid-derived suppressor cells in inflammatory bowel disease: a new immunoregulatory pathway. Gastroenterology 2008; 135: 871-881
10. Vuk-Pavlovic S, Bulur PA, Lin Y et al. Immunosuppressive CD14(1)HLA-DR(low/-) monocytes in prostate cancer. Prostate 2010; 70: 443-455
11. Kusmartsev S, Su Z, Heiser A et al. Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma. Clin Cancer Res 2008; 14: 8270-8278
12. Rodriguez PC, Ernstoff MS, Hernandez C et al. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpo-pulation of activated granulocytes. Cancer Res 2009; 69: 1553-1560
13. Diaz-Montero CM, Salem ML, Nishimura MI et al. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother 2009; 58: 49-59
14. Mirza N, Fishman M, Fricke I et al. All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res 2006; 66: 9299-9307 (Pubitemid 44521152)
15. Almand B, Resser JR, Lindman B et al. Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res 2000; 6: 1755-1766 (Pubitemid 30305068)
16. Zea AH, Rodriguez PC, Atkins MB et al. Arginase-producing mye-loid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res 2005; 65: 3044-3048 (Pubitemid 40524582)
17. Dugast AS, Haudebourg T, Coulon F et al. Myeloid-derived suppressor cells accumulate in kidney allograft tolerance and specifically suppress effector T cell expansion. J Immunol 2008; 180: 7898-7906
18. Varga G, Ehrchen J, Tsianakas A et al. Glucocorticoids induce an activated, anti-inflammatory monocyte subset in mice that resembles myeloid-derived suppressor cells. J Leukoc Biol 2008; 84: 644-650
19. Morelli AE, Thomson AW. Tolerogenic dendritic cells and the quest for transplant tolerance. Nat Rev Immunol 2007; 7: 610-621 (Pubitemid 47123548)
20. Chaput N, Conforti R, Viaud S et al. The Janus face of dendritic cells in cancer. Oncogene 2008; 27: 5920-5931
21. Lim WH, Kireta S, Thomson AW et al. Renal transplantation reverses functional deficiencies in circulating dendritic cell subsets in chronic renal failure patients. Transplantation 2006; 81: 160-168
22. Hackstein H, Renner FC, Bohnert A et al. Dendritic cell deficiency in the blood of kidney transplant patients on long-term immuno-suppression: results of a prospective matched-cohort study. Am J Transplant 2005; 5: 2945-2953 (Pubitemid 43923956)
23. Gerrits JH, Athanassopoulos P, Vaessen LM et al. Peripheral blood manipulation significantly affects the result of dendritic cell monitoring. Transpl Immunol 2007; 17: 169-177
24. Daniel V, Naujokat C, Sadeghi M et al. Observational support for an immunoregulatory role of CD31CD41CD251IFN-gamma1 blood lymphocytes in kidney transplant recipients with good long-term graft outcome. Transpl Int 2008; 21: 646-660 (Pubitemid 351852764)
25. Levey AS, Bosch JP, Lewis JB et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470 (Pubitemid 29135798)
26. McKenna KC, Beatty KM, Vicetti Miguel R et al. Delayed processing of blood increases the frequency of activated CD11b1 CD151 granulocytes which inhibit T cell function. J Immunol Methods 2009; 341: 68-75
27. Schmielau J, Finn OJ. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. Cancer Res 2001; 61: 4756-4760 (Pubitemid 32691887)
28. Solari MG, Thomson AW. Human dendritic cells and transplant outcome. Transplantation 2008; 85: 1513-1522
29. Bluth MJ, Zaba LC, Moussai D et al. Myeloid dendritic cells from human cutaneous squamous cell carcinoma are poor stimulators of T-cell proliferation. J Invest Dermatol 2009; 129: 2451-2462
30. Muhleisen B, Petrov I, Gachter T et al. Progression of cutaneous squamous cell carcinoma in immunosuppressed patients is associated with reduced CD1231 and FOXP31 cells in the perineoplastic inflammatory infiltrate. Histopathology 2009; 55: 67-76
31. Groux H, Bigler M, de Vries JE et al. Inhibitory and stimulatory effects of IL-10 on human CD81 T cells. J Immunol 1998; 160: 3188-3193 (Pubitemid 28164707)
32. Mocellin S, Marincola FM, Young HA. Interleukin-10 and the immune response against cancer: a counterpoint. J Leukoc Biol 2005; 78: 1043-1051 (Pubitemid 41572467)
33. Vouldoukis I, Becherel PA, Riveros-Moreno V et al. Interleukin-10 and interleukin-4 inhibit intracellular killing of Leishmania infantum and Leishmania major by human macrophages by decreasing nitric oxide generation. Eur J Immunol 1997; 27: 860-865 (Pubitemid 27153653)
34. Poschke I, Mougiakakos D, Hansson J et al. Immature immunosup-pressive CD141HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Res 2010; 70: 4335-4345
35. Duperrier K, Velten FW, Bohlender J et al. Immunosuppressive agents mediate reduced allostimulatory properties of myeloid-derived dendritic cells despite induction of divergent molecular phenotypes. Mol Immunol 2005; 42: 1531-1540 (Pubitemid 40798940)
36. Chalmin F, Ladoire S, Mignot G et al. Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immuno-suppressive function of mouse and human myeloid-derived suppressor cells. J Clin Invest 2010; 120: 457-471
37. Corzo CA, Condamine T, Lu L et al. HIF-1{alpha} regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med 2010; 207: 2439-2453
38. Marcil I, Stern RS. Risk of developing a subsequent nonmelanoma skin cancer in patients with a history of nonmelanoma skin cancer: a critical review of the literature and meta-analysis. Arch Dermatol 2000; 136: 1524-1530 (Pubitemid 32009273)
39. Stengel B. Chronic kidney disease and cancer: a troubling connection. J Nephrol 2010; 23: 253-262
40. Long MD, Kappelman MD, Pipkin CA. Nonmelanoma skin cancer in inflammatory bowel disease: a review. Inflamm Bowel Dis 2010; DOI: 10.1002/ibd.21484
41. Rafiq K, Charitidou L, Bullens DM et al. Regulation of the IL-10 production by human T cells. Scand J Immunol 2001; 53: 139-147 (Pubitemid 32154531)
42. Batiuk TD, Pazderka F, Enns J et al. Cyclosporine inhibition of calcineurin activity in human leukocytes in vivo is rapidly reversible. J Clin Invest 1995; 96: 1254-1260
43. Carroll RP, Segundo DS, Hollowood K et al. Immune phenotype predicts risk for posttransplantation squamous cell carcinoma. J Am Soc Nephrol 2010; 21: 713-722